Revenue Guidance was much more than I had hoped fo
Post# of 30028
Posted On: 09/02/2014 7:23:51 PM
Revenue Guidance was much more than I had hoped for! Here is what I heard.
In the year 2015 there will be spent 150 million by BP on AD diagnostics for their clinical trials. That 150 million is our overall potential market from clinical trials. Twice he said that he thought we'd get a significant portion of that. (Very vague.)
But he said we are going to save 30 to 40% on what Big Pharma is currently spending on their screening. So let's say we only get 40 million out of the 150 million. And then we get another 10 million from individuals who hear about Lympro from the media attention surrounding it. Together that amounts to 50 million revenue! Let's say we pay 10 million to ICON for fee for services. That leaves us 40 million in earnings for Lympro in 2015.
If you multiply those 40 million in earnings times a factor of 10 to arrive at a net present value, you get 400 million in market cap. For easy math, let assume we have 800 million outstanding shares. That leaves us with a net present value of .50 cents per share! Not bad!
This was the highlight of the CC for me. I think we are on track.
Let's be conservative and say we only do 60% as well as that?....instead of .50 cents only .30 cents? At .30 cents by December we could do a 1:10 RS and get to $3.00 so we could up list to NASDAQ.
In the year 2015 there will be spent 150 million by BP on AD diagnostics for their clinical trials. That 150 million is our overall potential market from clinical trials. Twice he said that he thought we'd get a significant portion of that. (Very vague.)
But he said we are going to save 30 to 40% on what Big Pharma is currently spending on their screening. So let's say we only get 40 million out of the 150 million. And then we get another 10 million from individuals who hear about Lympro from the media attention surrounding it. Together that amounts to 50 million revenue! Let's say we pay 10 million to ICON for fee for services. That leaves us 40 million in earnings for Lympro in 2015.
If you multiply those 40 million in earnings times a factor of 10 to arrive at a net present value, you get 400 million in market cap. For easy math, let assume we have 800 million outstanding shares. That leaves us with a net present value of .50 cents per share! Not bad!
This was the highlight of the CC for me. I think we are on track.
Let's be conservative and say we only do 60% as well as that?....instead of .50 cents only .30 cents? At .30 cents by December we could do a 1:10 RS and get to $3.00 so we could up list to NASDAQ.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼